| All subjects | Subjects aged 60 years or olderb | ||
---|---|---|---|---|
Baseline | Hazard ratio | 95% Confidence interval | Hazard ratio | 95% Confidence interval |
Age groups, years | Â | Â | Â | Â |
   50-59 | 0.06 | 0.05-0.08 | NA | NA |
   60-64c | 1.00 | - | - | - |
   ≥ 65 | 0.41 | 0.31-0.53 | 0.42 | 0.33-0.54 |
Women, n (%) | 1.13 | 0.95-1.35 | 1.17 | 0.97-1.41 |
Disease status | Â | Â | Â | Â |
   Rheumatoid arthritisd | 1.00 | - | - | - |
   Psoriatic arthritis | 1.58 | 0.86-2.91 | 1.27 | 0.63-2.59 |
   Psoriasis | 1.48 | 1.17-1.86 | 1.54 | 1.21-1.95 |
   Inflammatory bowel diseases | 1.71 | 1.36-2.14 | 1.64 | 1.29-2.09 |
   Ankylosing spondylitis | 1.45 | 0.71-2.97 | 1.23 | 0.54-2.79 |
   Multiple diseases | 1.00 | 0.72-1.39 | 1.01 | 0.71-1.43 |
History of herpes zoster infection | Â | Â | Â | Â |
   Nonee | 1.00 | - | - | - |
   Recent | 2.84 | 1.34-6.01 | 2.21 | 0.91-5.35 |
   Remote | 0.93 | 0.51-1.69 | 0.82 | 0.42-1.59 |
Medications (current use) | Â | Â | Â | Â |
   TNF antagonists | 0.47 | 0.33-0.67 | 0.41 | 0.27-0.61 |
   Other biologics (see Additional file 1) | 0.52 | 0.19-1.40 | 0.59 | 0.22-1.58 |
   Conventional DMARDs | 0.92 | 0.72-1.19 | 0.91 | 0.70-1.19 |
   Oral glucocorticoids |  |  |  |  |
Nonef | 1.00 | - | - | - |
Low/medium | 0.84 | 0.66-1.08 | 0.85 | 0.66-1.10 |
High | 0.46 | 0.15-1.45 | 0.53 | 0.17-1.68 |
Charlson co-morbidity index | Â | Â | Â | Â |
   0g | 1.00 | - | - | - |
   1 | 0.76 | 0.61-0.95 | 0.77 | 0.61-0.97 |
   ≥ 2 | 0.57 | 0.42-0.78 | 0.57 | 0.42-0.79 |
One or more inpatient physician visit | 0.53 | 0.40-0.72 | 0.50 | 0.37-0.69 |
Number of outpatient physician visits | Â | Â | Â | Â |
   0-2h | 1.00 | - | - | - |
   3-5 | 1.68 | 1.32-2.14 | 1.70 | 1.31-2.19 |
   6-10 | 1.80 | 1.39-2.34 | 1.80 | 1.37-2.38 |
   > 10 | 2.08 | 1.47-2.93 | 2.03 | 1.41-2.92 |
Influenza vaccine in the past year | 2.25 | 1.87-2.71 | 2.05 | 1.69-2.49 |
Pneumococcal vaccine in the past year | 1.79 | 1.45-2.21 | 1.81 | 1.45-2.26 |